OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Essel Discusses Adverse Events of Bevacizumab in Ovarian Cancer

May 25th 2018

Kathleen Essel, MD, fellow, University of Oklahoma Health Science Center, discusses adverse events with bevacizumab (Avastin) in ovarian cancer.

Dr. Succaria on Combination Immunotherapy in Head and Neck Cancer

May 25th 2018

Farah Succaria, MD, postdoctoral fellow, Johns Hopkins Medicine, discusses the potential for combination immunotherapy in the treatment of patients with head and neck cancer.

Dr. Snyder Discusses Emerging Agents in Myelofibrosis

May 25th 2018

David S. Snyder, MD, associate chair and professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses emerging agents in myelofibrosis.

Dr. Htut on Immunotherapy in Multiple Myeloma

May 25th 2018

Maung Myo Htut, MD, assistant clinical professor of hematology and hematopoietic cell transplantation, City of Hope, discusses the use of immunotherapy in the treatment of patients with multiple myeloma.

Dr. Slamon on PARP Inhibitors in Ovarian Cancer

May 25th 2018

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the use of PARP inhibitors in the treatment of patients with ovarian cancer.

Dr. Cohen on the Evolution of Surgery in Ovarian Cancer

May 25th 2018

Joshua G. Cohen, MD, assistant professor, Division of Gynecologic Oncology, University of California, Los Angeles, discusses the evolution of surgery in the treatment of patients with ovarian cancer.

Dr. Kopetz Discusses Triplet Therapy for BRAF-Mutant CRC

May 25th 2018

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses triplet therapy for patients with BRAF-mutant colorectal cancer

Dr. Ali Explains Misconceptions About Biosimilars

May 25th 2018

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses misconceptions about biosimilars in oncology.

Dr. Urbanic on the Evolution of Radiation in NSCLC

May 25th 2018

James Urbanic, MD, associate professor, Radiation Medicine and Applied Sciences, University of California, San Diego, discusses the evolution of radiation therapy in the treatment of patients with oligometastatic non–small cell lung cancer.

Dr. Ahn on Targeted Therapies in Gastric/Gastroesophageal Cancers

May 24th 2018

Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses targeted therapies in gastric/esophageal cancers.

Dr. Godwin on Immunotherapy Efforts in Prostate Cancer

May 24th 2018

James L. Godwin, MD, physician, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses immunotherapy efforts in prostate cancer.

Dr. Monk on the FORWARD I Trial in Ovarian Cancer

May 24th 2018

Bradley J. Monk, MD, FACOG, FACS, professor and director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph's Hospital and Medical Center, Arizona Oncology, discusses the FORWARD I trial in ovarian cancer.

Dr. Bekaii-Saab on the Use of Regorafenib in Patients With mCRC

May 24th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the use of regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).

Dr. Patel on Primary and Adaptive Resistance to Immunotherapy in NSCLC

May 24th 2018

Sandip P. Patel, MD, medical oncologist, assistant professor of medicine, University of California, San Diego, discusses primary and adaptive resistance to immunotherapy in non–small cell lung cancer (NSCLC).

Dr. Jhaveri on Acquired Resistance to CDK 4/6 Inhibitors in Breast Cancer

May 24th 2018

Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses acquired resistance to CDK 4/6 inhibitors in breast cancer.

Dr. Simone Discusses the Precision Promise Trial in Pancreatic Cancer

May 23rd 2018

Diane Simeone, MD, director, Pancreatic Cancer Center, associate director, Translational Research, NYU Langone’s Perlmutter Cancer Center, discusses the Precision Promise trial for patients with metastastic pancreatic cancer.

Dr. Mayor on Neuroendocrine Carcinoma in Gynecologic Tumors

May 23rd 2018

Paul Mayor, MD, Gynecologic Oncology Fellow, Roswell Park Cancer Institute, discusses neuroendocrine carcinoma in gynecologic tumors.

Dr. Perl on Remaining Challenges with CAR T-Cell Therapy

May 23rd 2018

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses remaining challenges with chimeric antigen receptor (CAR) T-cell therapy.

Dr. McGregor on New Combinations With Immunotherapy in RCC

May 23rd 2018

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses new combinations with immunotherapy in renal cell carcinoma.

Dr. Pegram Discusses the Use of Neratinib in HER2+ Breast Cancer

May 23rd 2018

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the use of neratinib (Nerlynx) in the treatment of patients with HER2-positive breast cancer.